Sleep Disordered Breathing with Opioid Use in Veterans
This study is for Veterans who use prescription opioids and have sleep apnea or other sleep-disordered breathing. Researchers want to see if oxygen (Hyperoxia) or a medication called acetazolamide can help reduce unstable breathing and sleep apnea in these individuals. They will measure how breathing changes and how the brain responds to carbon dioxide to understand if these interventions are effective. The study aims to improve understanding of how opioids affect breathing during sleep and ultimately develop better treatments. You may be eligible if you are a Veteran between 18 and 89 years old and use prescription opioids. The study's status is currently unclear, and it plans to enroll 150 participants.
- Study design
- This is an interventional study planning to enroll 150 participants. It will compare the effects of oxygen and acetazolamide to a placebo.
- What's involved
- Participants will ingest capsules (either placebo or acetazolamide) twice a day for 6 days. This includes physiology tests and an in-lab sleep study (PSG) on the final 4 nights.
- Compensation
- Not stated in the trial record.
- Follow-up
- Breathing instability and ventilatory responsiveness will be measured for up to 30 days, and cerebrovascular responsiveness for 7 days.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Sleep Disordered Breathing With Opioid Use
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Susmita Chowdhuri, MD MS · PRINCIPAL_INVESTIGATOR · John D. Dingell VA Medical Center, Detroit, MI
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Apneic threshold - a measure of breathing instability2 days to 30 days
Measures of breathing instability including: Apneic threshold: this is the end-tidal Co2 at which a central apnea closes to a hypopnea is produced.
- Cerebrovascular responsiveness to carbon-dioxide7 days
Cerebrovascular response to different levels of CO2: this is a measure of the response of the cerebral blood flow to changes in carbon dioxide levels and is used as a measure of ventilatory control of breathing
- Ventilatory responsiveness2 days to 30 days
Hypocapnic ventilatory response; this is calculated as the change in minute ventilation for corresponding changes in PETCO2.
- Carbon-dioxide reserve2 days to 30 days
This is a derived measure. This is calculated as the difference between the apneic threshold PETCO2 (given above) and the control PETCO2.